Addressing Challenges in Sarcoma Imaging and Finding Solutions in Clinical Trials

Sarcomas and bone tumors pose a distinctive challenge in oncology imaging, necessitating standardized protocols for precise tumor response determination in clinical trials. Multiple imaging techniques are needed to address the heterogeneity of these tumors.  Imaging Endpoints applies the leading and most successful methodologies to address the difficulties encountered in imaging sarcomas and bone tumors, including the use of multi-modal imaging in improving prognostic accuracy and treatment efficacy in clinical trials.

Sarcomas are a diverse group of tumors originating from mesenchymal tissues. These soft tissue and bone tumors are highly heterogeneous, encompassing a variety of subtypes that behave differently. This diversity demands a sophisticated and comprehensive approach to imaging for accurate diagnosis and monitoring, where conventional imaging techniques and assessment criteria like RECIST sometimes fall short, necessitating the integration of advanced approaches to overcome these challenges.

• Heterogeneity of Sarcomas and Multi-Modal Imaging: Employing a combination of imaging modalities such as CT, MRI, PET scans, and molecular imaging can provide a more detailed and accurate picture of sarcomas, which are complicated by their diverse nature with numerous subtypes.
• Advanced MRI Techniques: Diffusion-Weighted Imaging (DWI) assess cellularity by examining water molecule mobility within tissues, while Dynamic Contrast-Enhanced (DCE) imaging evaluates tumor vascularity and permeability changes, crucial for monitoring treatment effects.
• Evaluation of Treatment Response: Traditional size-based criteria like RECIST may not fully assess treatment efficacy, however imaging techniques like 18F-FDG PET can differentiate tumor grades, evaluate response, and predict prognosis based on metabolic activity.
• Radiomics and Machine Learning: Advanced computational methods like radiomics, using high-performance computing, and machine learning to analyze datasets, offer deeper insights into tumor biology. Delta-radiomics quantifies changes during treatment, providing additional information on tumor response.

Imaging Endpoints leads the way in collaborating with scientists, investigators, radiologists and regulatory experts to implement modifications and clarifications to the imaging criteria by integrating cutting-edge modalities. Through a perfect inspection record, industry-leading marketing authorization success rate, and advancing medical imaging, our experts are dedicated to improving your clinical trial outcomes.

To engage with our proficient medical and scientific affairs experts and explore tailored imaging solutions for your trials, emphasizing the significance of multi-modal approaches in shaping the future of sarcoma and bone tumor research.